Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

PhaseBio Shares Are on a Tear After Reporting Phase 2a Trial Results

The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects. In a press release issued September 24, PhaseBio Pharmaceuticals Inc. (PHAS...
Streetwise Reports | September 26, 2019 |

Quantum Economics, Negative Interest Rates and Financially Transmitted Diseases

This week the US Federal Reserve announced an emergency rate cut of 0.5% (50bps). It is part of a coordinated effort by central bankers around the world to keep the decade long bull market going a few days longer. Ultra low interest rates and ever depreciating currencie...
Marin Katusa | March 6, 2020 |

Gold vs Bitcoin: Quantum Economics and Financially Transmitted Diseases

It’s a common strategy in war. Addition by division. Put simply, adding content and flair by dividing two sides, is a very effective means of polarizing two or more sides. Cultural communists use it in their war on climate change “ You&CloseCurlyQu...
Marin Katusa | October 18, 2019 |

Our Fib Trading System is Telling Us Where The Market Is Headed Next

In this section of our multi-part research post centered around our Adaptive Fibonacci Price Modeling system’s expectations, we are focusing on the NQ (NASDAQ futures) and the future expected price rotations. As we discussed earlier, in Part I , Fibonacc...
Chris Vermeulen | April 9, 2020 |

Financially Transmitted Diseases

I came up with Financially Transmitted Disease, or FTD TM for short, a couple of years ago. It all happened when I was having dinner with some colleagues discussing quantitative easing (QE) and negative interest rate policy (NIRP). NIRP will have the biggest impact...
Marin Katusa | September 13, 2019 |

E-mini Dow Jones Industrial Average (YM) Futures Technical Analysis – Early Look Shows Market Holdin

The first short-term range is 28197 to 27312. Its 50% level or pivot at 27755 is support. It’s also controlling the near-term direction of the Dow. The range for the week is 28047 to 27726. Its 50% level is 27887. Aggressive traders may want to use this level ...
FX Empire | December 12, 2019 |

Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug

Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic ey...
Streetwise Reports | December 3, 2019 |

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases

The events in that trio are presented in a ROTH Capital Partners report. In a Feb. 3 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Albireo Pharma Inc. (ALBO:NASDAQ) plans to launch three clinical trials this year in the same num...
Streetwise Reports | February 10, 2020 |

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer...

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30% Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANG...
Streetwise Reports | October 8, 2019 |

Rare Diseases Biotech Provides Opportunity

A ROTH Capital Partners report discussed why the stock price is at its current level and noted upcoming catalysts for the company. In a March 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi indicated that the recent drop in Soleno Therapeutics Inc.'s (SL...
Streetwise Reports | March 22, 2019 |
1 2 3 4 5 6 7 8 9 10 ...